609807-34-3

Upstream product

• 81290-20-2 (trifluoromethyl)trimethylsilane 
• 609807-32-1 3-(4-fluoro-2-methoxyphenyl)-3-methylbutyronitrile 
• 609807-31-0 2-cyano-3-(4-fluoro-2-methoxyphenyl)-3-methylbutyric acid methyl ester 
• 51788-80-8 1-(4-fluoro-2-methoxy-phenyl)-ethanone 
• 1481-27-2 4-Fluoro-2-hydroxyacetophenone 
• 609807-33-2 3-(4-fluoro-2-methoxyphenyl)-3-methylbutyraldehyde 

Downstream Products

• 1562399-35-2 1-(5-aminopyrimidin-4-yl)-6-(4-fluoro-2-methoxyphenyl)-6-methyl-4-trifluoromethylhept-1-yn-4-ol 
• 1562399-32-9 C₁₆H₁₈F₄O₂ 
• 1562399-36-3 1,1,1-trifluoro-4-(3-fluoro-2-methoxyphenyl)-4-methyl-2-(5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)pentan-2-ol 
• 1562399-48-7 5-fluoro-2-[4,4,4-trifluoro-3-hydroxy-1,1-dimethyl-3-(5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)butyl]phenol 

Relevant academic research and scientific papers

Identification of highly efficacious glucocorticoid receptor agonists with a potential for reduced clinical bone side effects

Synthesis and structure-activity relationship (SAR) of a series of nonsteroidal glucocorticoid receptor (GR) agonists are described. These compounds contain "diazaindole" moieties and display different transcriptional regulatory profiles in vitro and are

GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF

Compounds of Formula (IA) and Formula (IB) wherein R1, R2, R3, R4, R5, and R6 are as defined herein for Formula (IA) or Formula (IB), or a tautomer, prodrug, solvate,or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.